Characterization of cardiac brain natriuretic peptide release in patients with paroxysmal atrial fibrillation undergoing left atrial ablation

Circulation: Arrhythmia and Electrophysiology

Volumn 3, Issue 1, 2010, Pages 18-23

  Gould, Paul A ^a   Gula, L J ^a   Bhayana, V ^a   Subbiah, R N ^a   Bentley, C ^a   Yee, Raymond ^a   Klein, George J ^a   Krahn, Andrew D ^a   Skanes, Allan C ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Ablation; Atrium; Natriuretic peptides

Indexed keywords

ANTIARRHYTHMIC AGENT; BRAIN NATRIURETIC PEPTIDE;

ABLATION THERAPY; ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY SINUS; FEMALE; HEART ACCESSORY CONDUCTION PATHWAY; HEART ATRIUM FIBRILLATION; HEART LEFT ATRIUM; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN SECRETION; TREATMENT RESPONSE; BLOOD; BLOOD PRESSURE; CATHETER ABLATION; HEART ATRIUM; HEART MUSCLE; HEART RATE; METABOLISM; MIDDLE AGED; PAROXYSMAL TACHYCARDIA; PATHOPHYSIOLOGY;

ADULT; BLOOD PRESSURE; CATHETER ABLATION; FEMALE; HEART ATRIA; HEART RATE; HUMANS; MALE; MIDDLE AGED; MYOCARDIUM; NATRIURETIC PEPTIDE, BRAIN; TACHYCARDIA, PAROXYSMAL;

EID: 77649292789     PISSN: 19413149     EISSN: 19413084     Source Type: Journal    
DOI: 10.1161/CIRCEP.108.831586     Document Type: Article

References (32)

1. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, Zamorano JL. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) : developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006; 114: e257-e354.
2. Deleted in proof.
3. Iwanaga Y, Nishi I, Furuichi S, Noguchi T, Sase K, Kihara Y, Goto Y, Nonogi H. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. J Am Coll Cardiol. 2006; 47: 742-748.
4. Inoue S, Murakami Y, Sano K, Katoh H, Shimada T. Atrium as a source of brain natriuretic polypeptide in patients with atrial fibrillation. J Card Fail. 2000; 6: 92-96.
5. Date T, Yamane T, Inada K, Matsuo S, Miyanaga S, Sugimoto KI, Shibayama K, Taniguchi I, Mochizuki S. Plasma brain natriuretic peptide levels in patients undergoing pulmonary vein isolation. Heart. 2006; 11: 1623-1627.
6. Yamada T, Murakami Y, Okada T, Okamoto M, Shimizu T, Toyama J, Yoshida Y, Tsuboi N, Ito T, Muto M, Kondo T, Inden Y, Hirai M, Murohara T. Plasma atrial natriuretic peptide and brain natriuretic peptide levels after radiofrequency catheter ablation of atrial fibrillation. Am J Cardiol. 2006; 97: 1741-1744.
7. Deleted in proof.
8. Martinek M, Nesser HJ, Aichinger J, Boehm G, Purerfellner H. Impact of integration of multislice computed tomography imaging into threedimensional electroanatomic mapping on clinical outcomes, safety, and efficacy using radiofrequency ablation for atrial fibrillation. Pacing Clin Electrophysiol. 2007; 30: 1215-1223.
9. Storti S, Prontera C, Emdin M, Passino C, Prati P, Fontani G, Giannelli I, Zyw L, Vittorini S, Zucchelli G, Clerico A. Analytical performance and clinical results of a fully automated MEIA system for brain natriuretic peptide assay: comparison with a point of care testing method. Clin Chem Lab Med. 2004; 42: 1178-1185.
10. Gould PA, D'Agostino J, Schneider HG, Kaye DM. Influence of atrial fibrillation on cardiac brain natriuretic peptide release during haemodynamic stress in heart failure. Eur J Heart Fail. 2006; 8: 263-269.
11. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc. 1995; 57: 289-300.
12. Sacher F, Corcuff JB, Schraub P, Le BV, Georges A, Jones SO, Lafitte S, Bordachar P, Hocini M, Clementy J, Haissaguerre M, Bordenave L, Roudaut R, Jais P. Chronic atrial fibrillation ablation impact on endocrine and mechanical cardiac functions. Eur Heart J. 2008; 29: 1290-1295.
13. Yamada T, Murakami Y, Okada T, Yoshida N, Toyama J, Yoshida Y, Tsuboi N, Inden Y, Hirai M, Murohara T. Plasma brain natriuretic peptide level after hybrid therapy with pulmonary vein isolation and antiarrhythmic drugs for atrial fibrillation. Int Heart J. 2008; 49: 143-151.
14. Liang F, Gardner DG. Mechanical strain activates BNP gene transcription through a p38/NF-kappaB-dependent mechanism. J Clin Invest. 1999; 104: 1603-1612.
15. Wozakowska-Kaplon B. Effect of sinus rhythm restoration on plasma brain natriuretic peptide in patients with atrial fibrillation. Am J Cardiol. 2004; 93: 1555-1558.
16. Shin DI, Jaekel K, Schley P, Sause A, Muller M, Fueth R, Scheffold T, Guelker H, Horlitz M. Plasma levels of NT-pro-BNP in patients with atrial fibrillation before and after electrical cardioversion. Z Kardiol. 2005; 94: 795-800.
17. Knudsen CW, Omland T, Clopton P, Westheim A, Wu AH, Duc P, McCord J, Nowak RM, Hollander JE, Storrow AB, Abraham WT, McCullough PA, Maisel A. Impact of atrial fibrillation on the diagnostic performance of B-type natriuretic peptide concentration in dyspneic patients: an analysis from the breathing not properly multinational study. J Am Coll Cardiol. 2005; 46: 838-844. (Pubitemid 41224808)
18. Rossi A, Enriquez-Sarano M, Burnett JC Jr, Lerman A, Abel MD, Seward JB. Natriuretic peptide levels in atrial fibrillation: a prospective hormonal and Doppler-echocardiographic study. J Am Coll Cardiol. 2000; 35: 1256-1262.
19. Kim BJ, Hwang SJ, Sung KC, Kim BS, Kang JH, Lee MH, Park JR. Assessment of factors affecting plasma BNP levels in patients with chronic atrial fibrillation and preserved left ventricular systolic function. Int J Cardiol. 2007; 118: 145-150.
20. Doyama K, Fukumoto M, Takemura G, Tanaka M, Oda T, Hasegawa K, Inada T, Ohtani S, Fujiwara T, Itoh H, Nakao K, Sasayama S, Fujiwara H. Expression and distribution of brain natriuretic peptide in human right atria. J Am Coll Cardiol. 1998; 32: 1832-1838.
21. Luchner A, Muders F, Dietl O, Friedrich E, Blumberg F, Protter AA, Riegger GA, Elsner D. Differential expression of cardiac ANP and BNP in a rabbit model of progressive left ventricular dysfunction. Cardiovasc Res. 2001; 51: 601-607.
22. von Ludinghausen M, Ohmachi N, Besch S, Mettenleiter A. Atrial veins of the human heart. Clin Anat. 1995; 8: 169-189.
23. Wang TJ, Larson MG, Levy D, Leip EP, Benjamin EJ, Wilson PW, Sutherland P, Omland T, Vasan RS. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol. 2002; 90: 254-258.
24. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol. 2007; 50: 2357-2368.
25. Vickery S, Price CP, John RI, Abbas NA, Webb MC, Kempson ME, Lamb EJ. B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy. Am J Kidney Dis. 2005; 46: 610-620.
26. Jais P, Peng JT, Shah DC, Garrigue S, Hocini M, Yamane T, Haissaguerre M, Barold SS, Roudaut R, Clementy J. Left ventricular diastolic dysfunction in patients with so-called lone atrial fibrillation. J Cardiovasc Electrophysiol. 2000; 11: 623-625.
27. Reant P, Lafitte S, Jais P, Serri K, Weerasooriya R, Hocini M, Pillois X, Clementy J, Haissaguerre M, Roudaut R. Reverse remodeling of the left cardiac chambers after catheter ablation after 1 year in a series of patients with isolated atrial fibrillation. Circulation. 2005; 112: 2896-2903.
28. Kupari M, Turto H, Lommi J, Makijarvi M, Parikka H. Transcardiac gradients of N-terminal B-type natriuretic peptide in aortic valve stenosis. Eur J Heart Fail. 2005; 7: 809-814.
29. Nagaya N, Nishikimi T, Uematsu M, Satoh T, Kyotani S, Sakamaki F, Kakishita M, Fukushima K, Okano Y, Nakanishi N, Miyatake K, Kangawa K. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation. 2000; 102: 865-870.
30. Mitaka C, Hirata Y, Nagura T, Tsunoda Y, Itoh M, Amaha K. Increased plasma concentrations of brain natriuretic peptide in patients with acute lung injury. J Crit Care. 1997; 12: 66-71.
31. Matsui T, Tsutamoto T, Maeda K, Kusukawa J, Kinoshita M. Prognostic value of repeated 123I-metaiodobenzylguanidine imaging in patients with dilated cardiomyopathy with congestive heart failure before and after optimized treatments: comparison with neurohumoral factors. Circ J. 2002; 66: 537-543.
32. Mukoyama M. Brain natriuretic peptide as a novel cardiac hormone in humans: evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest. 1991; 87: 1402-1412.